A wave of strategic deals, policy momentum, and technological breakthroughs defined the week for India’s drug manufacturers
India’s pharmaceutical sector is entering a transformative phase with AI and biologics powering the pharma innovation that will reshaping the industry’s future
Most office jobs today involve sitting for eight hours or more. Screens have replaced walking, and meetings have replaced movement.
India’s pharmaceutical ambitions are entering a decisive phase with the government announcing Rs 1,500 crore assistance fund
The global obesity treatment landscape is entering a transformative phase, As the new oral therapy begins to redefine patient's access to and adherence to weight loss medications
Biogen’s continued focus on developing an effective alzhiemers drug reflects progress and uncertainty in the global fight against the disease
India is positioning medical research as a central pillar in its long-term strategy to achieve developed nation status by 2047
Emcure has tightened its grip on Gennova with a Rs 231.8 crore acquisition. The deal will make Gennova a wholly owned subsidiary of the company.
Artificial intelligence (AI) is transforming every stage of the pharmaceutical value chain, from identifying disease targets to optimizing clinical trials and commercializing innovative therapies
Differentiated products in India are gaining strong momentum as pharmaceutical companies are increasingly focusing on innovation-led drug development to meet medical needs
.jpg)
, CDSCO.jpg)